A new Northwestern Medicine study published in the Proceedings of the National Academy of Sciences has explored the impacts ...
Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...
Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
The expanding interest in small bioactive peptides has brought renewed attention to glycyl-L-histidyl-L-lysine bound to ...
RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...
Scientists have solved a long-standing mystery by discovering the missing genetic ingredient that helps melanoma cells become ...
ATTR-CM treatment options narrowed after AstraZeneca and Ionis revealed their gene-silencing drug Wainua (eplontersen) failed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results